QFT-Plus Knowledge Hub
QFT-Plus Webinar Hub

Learn about TB testing from the experts

TB screening with confidence

Welcome to the webinar hub for QuantiFERON-TB Gold Plus (QFT-Plus) and TB testing.

The WHO now recommends systematic testing and treatment of latent TB infection – and universally supports modern blood tests for patients at risk (1). It’s time to move on from the skin test and join the TB testing revolution with QFT-Plus.

To learn more about the benefits of QFT-Plus testing and hear about the latest testing guidelines from the CDC, IDSA, USCIS and more, watch our most recent webinars.

  • Is screening and treatment of latent TB the key to TB elimination?
    Tuberculosis continues to threaten the lives of people worldwide as each year 10 million people develop this disease. Join Dr. Jean-Pierre Zellweger as he discusses the 2019 WHO TB report, new preventive treatment regimens and the benefits of using QuantiFERON-TB Gold Plus as a primary screening method to help reach the End TB Strategy targets.
    Is screening and treatment of latent TB the key to TB elimination?
  • QuantiFERON -TB Gold Plus: Is your practice up to date?
    Recent publications show the potential of QFT-Plus technology for at-risk patient populations — including contact investigation, healthcare worker screening and immunocompromised patients. In this webinar, Dr. Masae Kawamura discusses the latest scientific advancements in TB testing, including a review of recent publications and a discussion of case scenarios applying the insights of QFT-Plus.
    QuantiFERON -TB Gold Plus: Is your practice up to date?
  • Advancing healthcare provider TB testing with QuantiFERON-TB Gold Plus
    Healthcare providers (HCPs) are at increased risk for TB infection. Join Dr. Masae Kawamura, as she provides an overview of the standard policies and practices of screening HCPs for TB infection, new preventive treatment regimens, the use of IGRAs as a primary screening method and the benefits of QuantiFERON-TB Gold Plus.
    Advancing healthcare provider TB testing with QuantiFERON-TB Gold Plus
  • Latent tuberculosis infection in children
    The latest WHO guidelines strongly recommend diagnosis and treatment of latent TB infection for children age <5 years who are household contacts of active TB cases. In this webinar, Pr. Christophe Delacourt describes pediatric TB testing guidelines for the WHO, discusses clinical best practices and provides a review of the latest research in latent TB testing options.
    Latent tuberculosis infection in children
  • Insights on the development of a national health plan for TB
    Migrants are at increased risk for latent and active tuberculosis, and screening for latent TB infection is a critical component of a TB prevention and control strategy. Join Dr. Eskild Petersen as he discusses the the WHO goal of global elimination. Topics include migrant screening, the use of IGRA blood tests and the identification of at-risk populations.
    Insights on the development of a national health plan for TB
  • Protecting students from TB
    People living in dense housing arrangements – such as college dormitories – are at significantly increased risk of TB infection. Dr. Sonia Qasba describes recent TB exposures at US colleges, details testing recommendations from the ACHA and the CDC and describes how modern TB blood testing can improve the effectiveness and efficiency of college screening programs.
    Protecting students from TB
  • Management of TB infection in HIV co-infected patients
    People living with HIV are at increased risk for TB, and reliable surveillance is critical to protect their health. Join Dr. Delia Goletti to learn more about TB testing in patients living with HIV using QuantiFERON-TB Gold Plus. Topics include a review of published data and a discussion of the frontiers of TB diagnostic research.
    Management of TB infection in HIV co-infected patients
  • Occupational health screening for latent tuberculosis: an update
    The occupational health setting carries unique risks for TB infection and latent TB reactivation. Join Dr. Manish Pareek as he provides an overview of best practices for screening healthcare providers (HCPs) for TB infection, describes current global testing guidelines and provides a UK-specific perspective on TB screening in low-burden settings.
    Occupational health screening for latent tuberculosis: an update
  • Management of latent TB infection in patients requiring initiation of biologic therapy
    Join Dr. Vlad Nikolayevskyy as he provides an overview of the policies, practices and recent publications on screening patients requiring initiation of biologic therapy for TB infection. He also discusses new TB preventive treatment regimens and the use of IGRAs as a primary screening method.
    Manage latent TB infection prior to biologic therapy
  • Managing TB and HIV amidst the COVID-19 pandemic
    The COVID-19 pandemic has caused a global crisis with wide-reaching health and economic implications, including TB and HIV services. Join Dr. Sonia Qasba as she reviews screening for TB infection and prevention during these times, along with U.S. and global trends in COVID-19 epidemiology.
    Managing TB and HIV amidst the COVID-19 pandemic
  • The association between diabetes mellitus and latent TB infection
    Someone with untreated latent TB infection (LTBI) and diabetes is more likely to develop tuberculosis (TB) disease than someone without diabetes. In this webinar, Dr. Sonia Qasba journeys through the epidemiology, risk and treatment recommendations of diabetic patients with LTBI. She also discusses how diabetes potentiates TB and why TB predisposes one to hyperglycemia.
    The association between diabetes mellitus and latent TB infection
  • Is screening and treatment of latent TB the key to TB elimination?
    Is screening and treatment of latent TB the key to TB elimination?
  • QuantiFERON -TB Gold Plus: Is your practice up to date?
    QuantiFERON -TB Gold Plus: Is your practice up to date?
  • Advancing healthcare provider TB testing with QuantiFERON-TB Gold Plus
    Advancing healthcare provider TB testing with QuantiFERON-TB Gold Plus
  • Latent tuberculosis infection in children
    Latent tuberculosis infection in children
  • Insights on the development of a national health plan for TB
    Insights on the development of a national health plan for TB
  • Protecting students from TB
    Protecting students from TB
  • Management of TB infection in HIV co-infected patients
    Management of TB infection in HIV co-infected patients
  • Occupational health screening for latent tuberculosis: an update
    Occupational health screening for latent tuberculosis: an update
  • Manage latent TB infection prior to biologic therapy
    Management of latent TB infection in patients requiring initiation of biologic therapy
  • Managing TB and HIV amidst the COVID-19 pandemic
    Managing TB and HIV amidst the COVID-19 pandemic
  • The association between diabetes mellitus and latent TB infection
    The association between diabetes mellitus and latent TB infection

References:

1. WHO. (2018) Latent tuberculosis infection: Updated and consolidated guidelines for programmatic management. WHO/CDS/TB/2018.4.

QFT-Plus is an in vitro diagnostic aid for detection of Mycobacterium tuberculosis infection. QFT-Plus is an indirect test for M. tuberculosis infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations. QFT-Plus package inserts, up-to-date licensing information and product-specific disclaimers can be found at www.QuantiFERON.com

X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.
Confirm